Timothy J. Kotzé, Konrad J. Mostert, Riyad Domingo, Xu Wang, Wessel J. A. Moolman, Hailey S. Butman, Abigail Pepin, Kyle T. McKay, Deon P. Neveling, Joanna C. Evans, Valerie Mizrahi, Willem A. L. van Otterlo, Cynthia S. Dowd* and Erick Strauss*,
{"title":"代谢激活与隐藏前药:结核分枝杆菌和金黄色葡萄球菌中CoaBC的PPCS活性的双底物模拟抑制剂","authors":"Timothy J. Kotzé, Konrad J. Mostert, Riyad Domingo, Xu Wang, Wessel J. A. Moolman, Hailey S. Butman, Abigail Pepin, Kyle T. McKay, Deon P. Neveling, Joanna C. Evans, Valerie Mizrahi, Willem A. L. van Otterlo, Cynthia S. Dowd* and Erick Strauss*, ","doi":"10.1021/acsinfecdis.5c0004710.1021/acsinfecdis.5c00047","DOIUrl":null,"url":null,"abstract":"<p >The bifunctional bacterial CoaBC is a coenzyme A (CoA) biosynthetic protein that serves as a validated bactericidal target in <i>Mycobacterium tuberculosis</i> (Mtb). In <i>Staphylococcus aureus</i>, it is the target of the natural product antibiotic CJ-15,801, which inhibits its phosphopantothenoylcysteine synthetase (PPCS) activity by forming a bisubstrate mimic of its reactive reaction intermediate <i>in situ</i> after metabolic activation by pantothenate kinase, the first CoA biosynthetic enzyme. We prepared PPCS bisubstrate mimics with various stable linkers that would also require metabolic activation and used purified Mtb and <i>S. aureus</i> enzymes to evaluate their inhibition. Additionally, we prepared masked prodrug versions of the phosphorylated (activated) form of CJ-15,801 and tested these and the bisubstrate mimics, as whole-cell inhibitors of Mtb and <i>S. aureus</i>. We demonstrate that such inhibitors hold promise for the development of antimicrobials targeting these organisms, although further structure–activity relationship studies are necessary to address current challenges and improve their potency.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":"11 6","pages":"1508–1517 1508–1517"},"PeriodicalIF":3.8000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acsinfecdis.5c00047","citationCount":"0","resultStr":"{\"title\":\"Metabolic Activation versus Masked Prodrugs: Bisubstrate Mimic Inhibitors of CoaBC’s PPCS Activity in Mycobacterium tuberculosis and Staphylococcus aureus\",\"authors\":\"Timothy J. Kotzé, Konrad J. Mostert, Riyad Domingo, Xu Wang, Wessel J. A. Moolman, Hailey S. Butman, Abigail Pepin, Kyle T. McKay, Deon P. Neveling, Joanna C. Evans, Valerie Mizrahi, Willem A. L. van Otterlo, Cynthia S. Dowd* and Erick Strauss*, \",\"doi\":\"10.1021/acsinfecdis.5c0004710.1021/acsinfecdis.5c00047\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >The bifunctional bacterial CoaBC is a coenzyme A (CoA) biosynthetic protein that serves as a validated bactericidal target in <i>Mycobacterium tuberculosis</i> (Mtb). In <i>Staphylococcus aureus</i>, it is the target of the natural product antibiotic CJ-15,801, which inhibits its phosphopantothenoylcysteine synthetase (PPCS) activity by forming a bisubstrate mimic of its reactive reaction intermediate <i>in situ</i> after metabolic activation by pantothenate kinase, the first CoA biosynthetic enzyme. We prepared PPCS bisubstrate mimics with various stable linkers that would also require metabolic activation and used purified Mtb and <i>S. aureus</i> enzymes to evaluate their inhibition. Additionally, we prepared masked prodrug versions of the phosphorylated (activated) form of CJ-15,801 and tested these and the bisubstrate mimics, as whole-cell inhibitors of Mtb and <i>S. aureus</i>. We demonstrate that such inhibitors hold promise for the development of antimicrobials targeting these organisms, although further structure–activity relationship studies are necessary to address current challenges and improve their potency.</p>\",\"PeriodicalId\":17,\"journal\":{\"name\":\"ACS Infectious Diseases\",\"volume\":\"11 6\",\"pages\":\"1508–1517 1508–1517\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2025-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://pubs.acs.org/doi/epdf/10.1021/acsinfecdis.5c00047\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acsinfecdis.5c00047\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsinfecdis.5c00047","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Metabolic Activation versus Masked Prodrugs: Bisubstrate Mimic Inhibitors of CoaBC’s PPCS Activity in Mycobacterium tuberculosis and Staphylococcus aureus
The bifunctional bacterial CoaBC is a coenzyme A (CoA) biosynthetic protein that serves as a validated bactericidal target in Mycobacterium tuberculosis (Mtb). In Staphylococcus aureus, it is the target of the natural product antibiotic CJ-15,801, which inhibits its phosphopantothenoylcysteine synthetase (PPCS) activity by forming a bisubstrate mimic of its reactive reaction intermediate in situ after metabolic activation by pantothenate kinase, the first CoA biosynthetic enzyme. We prepared PPCS bisubstrate mimics with various stable linkers that would also require metabolic activation and used purified Mtb and S. aureus enzymes to evaluate their inhibition. Additionally, we prepared masked prodrug versions of the phosphorylated (activated) form of CJ-15,801 and tested these and the bisubstrate mimics, as whole-cell inhibitors of Mtb and S. aureus. We demonstrate that such inhibitors hold promise for the development of antimicrobials targeting these organisms, although further structure–activity relationship studies are necessary to address current challenges and improve their potency.
期刊介绍:
ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to:
* Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials.
* Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets.
* Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance.
* Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents.
* Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota.
* Small molecule vaccine adjuvants for infectious disease.
* Viral and bacterial biochemistry and molecular biology.